Is an effective immune intervention for Alzheimer's disease in prospect?
Alzheimer's disease is characterized in part by abnormal deposits in the brain of the peptide beta amyloid (Abeta), in the form of plaques. Recent work with a transgenic model of Abeta deposition has uncovered a remarkable capacity of antibodies to prevent or clear these deposits. These experiments offer the attractive possibility, albeit some way in the future, of using antibodies as a therapy in Alzheimer's disease.
Esiri
M M
MM
Departments of Clinical Neurology and Neuropathology, University of Oxford, Radcliffe Infirmary, Woodstock Road, OX2 6HE, Oxford, UK. margaret.esiri@cineuro.ox.ac.uk
D000544:Alzheimer Disease / Q000378:metabolism / Q000517:prevention & control / Q000628:therapy*; D016229:Amyloid beta-Peptides / Q000276:immunology* / Q000378:metabolism; D000818:Animals; D006801:Humans; D007114:Immunization; D051379:Mice; D008822:Mice, Transgenic; D010446:Peptide Fragments / Q000276:immunology*
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)